Study of Bcl-2 Inhibitor Sonrotoclax (BGB-11417) in Participants With Mature B-Cell Malignancies

← catalyst calendar

NCT04277637 · readout in 285 d

Sponsored by BeOne Medicines (industry) · ONC — their whole pipeline →.

Phase

Phase 1

Status

Active, not recruiting

Study type

Interventional

Design

Non randomized · None · Treatment

Enrollment

437actual

Sites

Countries

Australia, Germany, Italy +4

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2020-03-24

actual

When the study began enrolling

Primary completion

2027-05-31

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2027-05-31

estimated

The whole study's end, after follow-up

First posted

2020-02-20

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-06-22

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Mature B-Cell Malignancies

Interventions

Drug: Sonrotoclax — also filed as BGB-11417
Drug: Zanubrutinib — also filed as BGB-3111
Drug: Obinutuzumab

Primary outcomes

what the primary-completion date above is the date OF

Number of Participants Experiencing Treatment Emergent Adverse Events (TEAEs)

measured Up to 30 days after the last dose of study drug, an average of 18 months

Number of Participants Experiencing Serious Adverse Events (SAEs)

measured Up to 30 days after the last dose of study drug, an average of 18 months

Number of Participants Experiencing Adverse Events (AEs) leading to discontinuation of Sonrotoclax

measured Up to 30 days after the last dose of study drug, an average of 18 months

Part 1, Part 3: Maximum Tolerated Dose (MTD) of Sonrotoclax

measured Up to approximately 2 months

Part 1, Part 3, Part 5: RP2D of Sonrotoclax

measured Day 1 to last dose of study drug, an average of 18 months

Part 1, Part 3, Part 5: Number of participants experiencing tumor lysis syndrome (TLS) relevant events

measured Up to 30 days after the last dose of study drug, an average of 18 months

Part 1, Part 3, Part 5: Number of Participants Experiencing Dose-Limiting Toxicities (DLTs

measured Up to approximately 2 months

Permalink · ONC's whole pipeline · Catalyst calendar · Every registered study · What changed